Clinical Trials Logo

TP53 Mutation clinical trials

View clinical trials related to TP53 Mutation.

Filter by:
  • None
  • Page 1

NCT ID: NCT06413992 Recruiting - Clinical trials for Endometrial Carcinoma

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Start date: May 10, 2024
Phase: Phase 2
Study type: Interventional

This study is an open-label Phase II randomized controlled trial designed to evaluate the safety and efficacy of camrelizumab plus fluzoparib maintenance therapy in patients with recurrent or metastatic TP-53 mutated Endometrial Cancer. The study will also explore the prevalence of homologous recombination reficiency in Chinese patients with TP-53 mutated endometrial cancer and its therapeutic significance.

NCT ID: NCT04510584 Withdrawn - Clinical trials for Fallopian Tube Cancer

Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer

Start date: July 16, 2021
Phase: Phase 2
Study type: Interventional

This study is being done to look at the combination of the drugs atezolizumab and bevacizumab as a maintenance treatment (treatment given after the main treatment to keep the cancer from coming back or worsening) following standard therapy in patients with high grade ovarian, fallopian tube, or primary peritoneal cancer with a mutation (change) in a gene called TP53. Genes are molecules in the body that are made up of deoxyribonucleic acid (DNA) and control how the body's cells behave.

NCT ID: NCT04023916 Not yet recruiting - Clinical trials for Diffuse Large B-Cell Lymphoma

Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.

Start date: December 1, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Sintilimab and R-CHOP regimen as the first-line treatment for DLBCL patients with TP53 mutation and PD-L1 positive.